控制释放透药物输送系统的微制造,由设计元素组装成
Bence Borbás1, Nikolett Kállai-Szabó1, Miléna Lengyel1
1Department of Pharmaceutics, Semmelweis University, Budapest, Hungary.
Expert opinion on drug delivery
|October 5, 2024
概括
这项研究开发了一种新的3D打印的透药物递送系统 (DDS),实现零顺序的药物释放. 这种模块化DDS提供可定制,可控制的药物输送,用于个性化治疗.
科学领域:
- 制药科学 制药科学
- 材料科学 材料科学 材料科学
- 生物医学工程 生物医学工程
背景情况:
- 研究一种新的多组件,可控释放药物递送系统 (DDS).
- 将3D打印与传统压缩方法相结合.
- 使用透性平板电脑层和半透膜来控制药物释放.
研究的目的:
- 开发和描述一个3D打印,模块化,控制释放的药物输送系统.
- 评估系统实现零顺序药物释放动力学的能力.
- 探索个性化医疗应用的潜力.
主要方法:
- 在3D打印的框架内开发了一种具有直接压缩的推拉平板电脑层的DDS.
- 使用纤维素酸盐和可塑剂 (甘油,乙烯甘醇) 制造出半透膜.
- 采用正子灭寿命光谱 (PALS) 进行微观结构和可湿性分析,以及其他表征技术.
主要成果:
- 糖增强了膜湿透性,得到了PALS的证实.
- 实现稳定,零顺序的药物释放动力学,独立于速率.
- 成功证明了对氨酸化物有效的药物输送控制.
结论:
- 成功创建了一个具有零顺序释放动力学的受控释放透DDS的原型.
- 模块化,3D打印设计使得护理点的定制成为可能.
- 呈现了一个有前途的平台,用于人体和兽医药物个性化药物输送.
相关概念视频
Modified-Release Drug Delivery Systems: Rate-Programmed II
139
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
139
Drug Delivery Systems: Different Types
418
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
418
Modified-Release Drug Delivery Systems: Classification
318
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
318
Modified-Release Drug Delivery Systems: Rate-Programmed I
174
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
174
Modified-Release Drug Delivery Systems: Stimuli-Activated
184
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
184
Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167


